Abstract
A simple method is reported to synthesize an anticancer drug, NCX 4040, conveniently in mild conditions using silicon chemistry. A starting material, 4-hydroxybenzyl alcohol, was silylated selectively first to give tbutyldimethylsilyl 4-hydroxybenzyl ether, which was then converted to NCX 4040 by esterification, desilylation, hydrochlorination and nitration.
Keywords: Anticancer drug, NCX 4040, design, synthesis, mild conditions, LNCaP cancer cell lines, prostate cancer
Letters in Organic Chemistry
Title: Facile Synthesis of Anticancer Drug NCX 4040 in Mild Conditions
Volume: 5 Issue: 7
Author(s): Mei Xiao, Hongsong Yang, Suzane M. Klein, Christian M. Muenyi, William L. Stone and Yu L. Jiang
Affiliation:
Keywords: Anticancer drug, NCX 4040, design, synthesis, mild conditions, LNCaP cancer cell lines, prostate cancer
Abstract: A simple method is reported to synthesize an anticancer drug, NCX 4040, conveniently in mild conditions using silicon chemistry. A starting material, 4-hydroxybenzyl alcohol, was silylated selectively first to give tbutyldimethylsilyl 4-hydroxybenzyl ether, which was then converted to NCX 4040 by esterification, desilylation, hydrochlorination and nitration.
Export Options
About this article
Cite this article as:
Xiao Mei, Yang Hongsong, Klein M. Suzane, Muenyi M. Christian, Stone L. William and Jiang L. Yu, Facile Synthesis of Anticancer Drug NCX 4040 in Mild Conditions, Letters in Organic Chemistry 2008; 5 (7) . https://dx.doi.org/10.2174/157017808785982257
DOI https://dx.doi.org/10.2174/157017808785982257 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and Characterization of Coaxial Electrospun Fibers Containing Triclosan for Comparative Study of Release Properties with Amoxicillin and Epicatechin
Current Drug Delivery From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Sequence and Structural Elements in the Mechanism of Function of Rhodopsin-Like Family of G Protein-Coupled-Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Synthesis and Characterization of Water-soluble Conjugates of Cabazitaxel Hemiesters-Dextran
Anti-Cancer Agents in Medicinal Chemistry NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets SERMs: Evolutionary Chemistry, Revolutionary Biology
Current Pharmaceutical Design The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Kisspeptin: A Critical Regulator of Puberty and Reproductive Function
Current Drug Targets Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Merkel Cell Carcinoma – Current State and the Future
Current Cancer Therapy Reviews Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition